Undisclosed Trilomer® program
Cancer (target: HER2)
Key Facts
About Trilo Therapeutics
Trilo Therapeutics is pioneering a new modality in targeted oncology with its Trilomer® platform, which utilizes DNA-encoded libraries to discover macrocyclic D-peptide drug conjugates. These molecules are engineered for superior tumor penetration, protease resistance, and reduced renal uptake compared to antibodies and L-peptides, potentially offering a safer and more effective delivery vehicle for cytotoxic payloads. The company is in active preclinical development against several clinically validated ADC targets, positioning itself to address significant unmet needs in cancer therapy. As a private, pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and validating its platform's advantages.
View full company profileAbout Trilo Therapeutics
Trilo Therapeutics is pioneering a new modality in targeted oncology with its Trilomer® platform, which utilizes DNA-encoded libraries to discover macrocyclic D-peptide drug conjugates. These molecules are engineered for superior tumor penetration, protease resistance, and reduced renal uptake compared to antibodies and L-peptides, potentially offering a safer and more effective delivery vehicle for cytotoxic payloads. The company is in active preclinical development against several clinically validated ADC targets, positioning itself to address significant unmet needs in cancer therapy. As a private, pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and validating its platform's advantages.
View full company profileAbout Trilo Therapeutics
Trilo Therapeutics is pioneering a new modality in targeted oncology with its Trilomer® platform, which utilizes DNA-encoded libraries to discover macrocyclic D-peptide drug conjugates. These molecules are engineered for superior tumor penetration, protease resistance, and reduced renal uptake compared to antibodies and L-peptides, potentially offering a safer and more effective delivery vehicle for cytotoxic payloads. The company is in active preclinical development against several clinically validated ADC targets, positioning itself to address significant unmet needs in cancer therapy. As a private, pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and validating its platform's advantages.
View full company profileAbout Trilo Therapeutics
Trilo Therapeutics is pioneering a new modality in targeted oncology with its Trilomer® platform, which utilizes DNA-encoded libraries to discover macrocyclic D-peptide drug conjugates. These molecules are engineered for superior tumor penetration, protease resistance, and reduced renal uptake compared to antibodies and L-peptides, potentially offering a safer and more effective delivery vehicle for cytotoxic payloads. The company is in active preclinical development against several clinically validated ADC targets, positioning itself to address significant unmet needs in cancer therapy. As a private, pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and validating its platform's advantages.
View full company profile